Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Drug

Dupixent Secures Back-to-Back COPD Approvals from US FDA and China NMPA

Fineline Cube Sep 29, 2024

Regeneron (NASDAQ: REGN), a leading biopharmaceutical company based in the U.S., in collaboration with its...

Company Drug

AbbVie Submits First BLA for c-Met Targeting ADC Telisotuzumab Vedotin to FDA

Fineline Cube Sep 29, 2024

AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company in the U.S., has announced the filing...

Company Deals

Whittilong Pharma Secures Over RMB 100 Million in Series B Financing for Modified Drug Development

Fineline Cube Sep 29, 2024

Whittilong Pharma, a Shanghai-based modified drug development company backed by Shanghai Healthcare Capital (SHC), has...

Company

HOYA Surgical Optics Expands in China with New Artificial Intraocular Lens Facility

Fineline Cube Sep 29, 2024

HOYA Surgical Optics has established its presence in the Suzhou High-Tech Zone of Jiangsu province,...

Company Deals

Shanghai Pharmaceuticals Partners with SIBPT to Boost Biopharmaceutical R&D and Translation

Fineline Cube Sep 29, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has entered into a partnership with the Shanghai...

Company Drug

Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04

Fineline Cube Sep 29, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based...

Company Drug

Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review

Fineline Cube Sep 29, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company

3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline

Fineline Cube Sep 29, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the...

Policy / Regulatory

China Sets New Management Measures for Investigator-Initiated Trials in Medical Institutions

Fineline Cube Sep 29, 2024

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Policy / Regulatory

China Unveils Medical Insurance Eligibility Management System for Designated Healthcare Personnel

Fineline Cube Sep 29, 2024

The National Healthcare Security Administration (NHSA), National Health Commission, and National Medical Products Administration (NMPA)...

Company Deals

OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor

Fineline Cube Sep 28, 2024

Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution...

Company Drug

Jacobio Pharma Receives NMPA Approval for Pan-KRAS Inhibitor JAB-23E73 Clinical Trial

Fineline Cube Sep 27, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has received approval from the...

Company Drug

AstraZeneca’s Tagrisso Secures FDA Approval for Unresectable Stage III EGFRm NSCLC

Fineline Cube Sep 27, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN), a UK-based pharmaceutical giant, has announced that it has received...

Company Deals

Jacobio Pharma Receives RMB 172 Million Milestone Payment from Allist Pharmaceuticals

Fineline Cube Sep 27, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced the receipt of...

Company Deals

Apeloa Pharmaceutical Partners with Biocre Tech to Boost Pharmaceutical Innovation

Fineline Cube Sep 27, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a pharmaceutical company based in China, has entered into...

Company Deals

FDA Approves Cobenfy as Novel Schizophrenia Treatment with First-in-Decades Mechanism

Fineline Cube Sep 27, 2024

The U.S. Food and Drug Administration (FDA) has granted official approval to Cobenfy (KarXT, xanomeline...

Policy / Regulatory

Hunan Province Includes Fertility Treatments in Medical Insurance Coverage from October 2024

Fineline Cube Sep 27, 2024

The Hunan Healthcare Security Administration has issued a notification to include specific assisted reproductive medical...

Company Deals

Shanghai Junshi Biosciences Inks Licensing Deal for IAMA-001 Nasal Spray with Nanjing JSIAMA

Fineline Cube Sep 27, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a biopharmaceutical company based in China,...

Company

China’s Pharmaceutical Industry Sees Mixed Results in H1 2024, CAPEM Data Reveals

Fineline Cube Sep 27, 2024

The China Association of Pharmaceutical Enterprises Management (CAPEM) has released a comprehensive set of data...

Policy / Regulatory

Shanghai Medical Procurement Platform Sets Price Cap for Non-Locally Supplied Drugs

Fineline Cube Sep 27, 2024

Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) has issued a notification concerning the online procurement prices...

Posts pagination

1 … 282 283 284 … 657

Recent updates

  • Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
  • Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China
  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.